Status Suspended
Decision Selected
Process TA
Referral date 01 November 2005
Topic area
  • Endocrine, nutritional and metabolic
  • Eye

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC


Key events during the development of the guidance:

Date Update
25 August 2006 This topic was referred by the Department of Health and the Welsh Assembly Government as part of the Institute's 12th wave work programme.
10 January 2007 Communications manager changed
17 April 2007 The manufacturer of ruboxistaurin has advised us that they have withdrawn regulatory applications in relation to this product at this time. The Institute has therefore decided to remove this appraisal from its work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual